Table 1 Patient characteristics at time of switch to second-line anti-retroviral regimen
Characteristic | ATV/r | LPV/r | P value |
|---|---|---|---|
Eligible | 252 | 225 | |
Included, n (%) | 224 (88.8) | 205 (91.1) | 0.663 |
Sex, n (%) | |||
Female | 148 (66.1) | 128 (62.4) | 0.223 |
Male | 76 (33.9) | 77 (37.6) | |
Age (years), median (IQR) | 37 (30–42) | 36 (31–42) | 0.792 |
Grouped BMI, Kg/m2, n (%)a | |||
Under weight | 15 (6.9) | 21 (11.4) | 0.305 |
Normal | 137 (63.4) | 111 (60.0) | |
Over weight | 64 (29.6) | 53 (28.7) | |
Missing | 8 | 20 | |
First-line drug, n (%) | |||
NVP | 144 (64.3) | 132 (64.4) | 0.982 |
EFV | 80 (35.7) | 73 (35.6) | |
CD4 count cell/μl, median (IQR) | 118 (59–214) | 102 (59–189) | 0.088 |
Viral load Log 10 copies/ml at switch to second- line, median (IQR) | 4.5 (3.8–4.9) | 4.5 (3.2–5.1) | 0.421 |
Duration (months) on first-line therapy, median (IQR) | 56 (28–80) | 46 (25–67) | 0.025 |
Duration (months on second-line by time of viral load, median (IQR) | 19 (21–25) | 40 (32–52) | < 0.001 |
NRTI drugs in second line, n (%) | |||
3TC-TDF | 191 (85.3) | 154 (75.1) | 0.741 |
3TC-AZT | 29 (12.9) | 48 (23.4) | |
3TC-ABC | 4 (1.8) | 3 (1.5) | |